Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fisogatinib (BLU-554) 是高效的、选择性的、口服具有活力的 FGFR4 抑制剂(IC50:5 nM)。它在依赖FGFR4信号传导的肝细胞癌模型中具有显著的抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 443 | 现货 | ||
2 mg | ¥ 597 | 现货 | ||
5 mg | ¥ 945 | 现货 | ||
10 mg | ¥ 1,650 | 现货 | ||
25 mg | ¥ 3,280 | 现货 | ||
50 mg | ¥ 4,820 | 现货 | ||
100 mg | ¥ 6,880 | 现货 | ||
500 mg | ¥ 13,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,130 | 现货 |
产品描述 | Fisogatinib (BLU-554) is a potent inhibitor of fibroblast growth factor receptor 4 (FGFR4). |
靶点活性 | FGFR4:5 nM |
体外活性 | BLU-554 exploits a unique interaction with FGFR4 to confer potency and selectivity |
体内活性 | BLU-554 is well tolerated in these tumor models. Administration of BLU-554 induces tumor regression in liver cancer models[1]. |
激酶实验 | The Ki value and mode of inhibition of LY2801653 for the MET kinase activity are determined using a radiometric filter-binding assay. Reactions are carried out in 96-well plates in Enzyme dilution buffer (EDB) compose of 50 mM Tris HCl pH 7.5, 2 mM DTT, 0.005% Triton X-100, 10 mM MgCl2, and 250 ?M EDTA. Serially diluted LY2801653 (final concentration 250 to 0 nM) are followed by the addition of a series of 8 concentrations of 33P-γ-ATP (final concentration 400 to 10 μM ATP), and 5 nM enzyme (final concentration). After a 2-hour incubation, PolyGluTyr synthetic protein substrate (final 150 μg/mL) is added to initiate the 30-minute kinase reaction. Reactions are quenched with 10% H3PO4, transfer to a pre-wetted Multiscreen anionic phosphocellulose 96-well filter plate, and washed; radioactivity is measured with a scintillation counter. The experimental data are fit to a global mix model inhibition equation using GraphPad Prism softwar to generate an alpha value to determine the modality of inhibition and to calculate the Ki value for LY2801653[1]. |
别名 | BLU554, BLU 554, BLU-554 |
分子量 | 503.38 |
分子式 | C24H24Cl2N4O4 |
CAS No. | 1707289-21-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 2 mg/mL (3.97 mM)
DMSO: 93 mg/mL (184.8 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 1.9866 mL | 9.9329 mL | 19.8657 mL | 49.6643 mL |
DMSO | 5 mM | 0.3973 mL | 1.9866 mL | 3.9731 mL | 9.9329 mL |
10 mM | 0.1987 mL | 0.9933 mL | 1.9866 mL | 4.9664 mL | |
20 mM | 0.0993 mL | 0.4966 mL | 0.9933 mL | 2.4832 mL | |
50 mM | 0.0397 mL | 0.1987 mL | 0.3973 mL | 0.9933 mL | |
100 mM | 0.0199 mL | 0.0993 mL | 0.1987 mL | 0.4966 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fisogatinib 1707289-21-1 Angiogenesis Tyrosine Kinase/Adaptors FGFR inhibit BLU554 Fibroblast growth factor receptor BLU 554 BLU-554 Inhibitor inhibitor